Global
# |
Name |
Share Price |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 411.66 |
Jan. 14, 2025 | USD 411.66 | -0.41% |
|
United States |
|
2 |
USD 330.91 |
Jan. 14, 2025 | USD 330.91 | -5.99% |
|
United States |
|
3 |
USD 274.12 |
Jan. 14, 2025 | USD 274.12 | -9.74% |
|
United States |
|
4 |
USD 240.51 |
Jan. 14, 2025 | USD 240.51 | -6.88% |
|
United States |
|
5 |
USD 216.88 |
Jan. 14, 2025 | USD 216.88 | 1.28% |
|
Denmark |
|
6 |
USD 200.24 |
Jan. 14, 2025 | USD 200.24 | -8.14% |
|
Ireland |
|
7 |
USD 178.08 |
Jan. 14, 2025 | USD 178.08 | -6.34% |
|
United States |
|
8 |
USD 142.64 |
Jan. 14, 2025 | USD 142.64 | -5.10% |
|
United States |
|
9 |
USD 139.51 |
Jan. 14, 2025 | USD 139.51 | -2.46% |
|
United States |
|
10 |
USD 126.89 |
Jan. 14, 2025 | USD 126.89 | -0.24% |
|
United States |
|
11 |
USD 118.83 |
Jan. 14, 2025 | USD 118.83 | 0.34% |
|
United States |
|
12 |
USD 116.36 |
Jan. 14, 2025 | USD 116.36 | -0.45% |
|
Germany |
|
13 |
USD 102.56 |
Jan. 14, 2025 | USD 102.56 | -0.77% |
|
United States |
|
14 |
USD 84.60 |
Jan. 14, 2025 | USD 84.60 | -5.23% |
|
United States |
|
15 |
USD 80.54 |
Jan. 14, 2025 | USD 80.54 | 1.08% |
|
||
16 |
USD 72.39 |
Jan. 14, 2025 | USD 72.39 | 0.74% |
|
United States |
|
17 |
USD 71.93 |
Jan. 14, 2025 | USD 71.93 | -0.61% |
|
United States |
|
18 |
USD 65.84 |
Jan. 14, 2025 | USD 65.84 | 2.84% |
|
United States |
|
19 |
USD 64.65 |
Jan. 14, 2025 | USD 64.65 | -4.02% |
|
United States |
|
20 |
USD 57.83 |
Jan. 14, 2025 | USD 57.83 | -1.55% |
|
United States |
|
21 |
USD 54.36 |
Jan. 14, 2025 | USD 54.36 | -2.16% |
|
United States |
|
22 |
USD 51.66 |
Jan. 14, 2025 | USD 51.66 | 1.18% |
|
United States |
|
23 |
USD 46.50 |
Jan. 14, 2025 | USD 46.50 | 2.74% |
|
Switzerland |
|
24 |
USD 45.35 |
Jan. 14, 2025 | USD 45.35 | 0.64% |
|
United States |
|
25 |
USD 45.23 |
Jan. 14, 2025 | USD 45.23 | -3.17% |
|
United States |
|
26 |
USD 43.32 |
Jan. 14, 2025 | USD 43.32 | -1.54% |
|
United States |
|
27 |
USD 42.54 |
Jan. 14, 2025 | USD 42.54 | -1.21% |
|
United States |
|
28 |
USD 39.83 |
Jan. 14, 2025 | USD 39.83 | -6.44% |
|
United States |
|
29 |
USD 39.65 |
Jan. 14, 2025 | USD 39.65 | 3.66% |
|
Canada |
|
30 |
USD 39.01 |
Jan. 14, 2025 | USD 39.01 | -3.56% |
|
Netherlands |
|
31 |
USD 37.82 |
Jan. 14, 2025 | USD 37.82 | 0.66% |
|
United States |
|
32 |
USD 37.46 |
Jan. 14, 2025 | USD 37.46 | -1.68% |
|
United States |
|
33 |
USD 36.67 |
Jan. 14, 2025 | USD 36.67 | -1.26% |
|
United States |
|
34 |
USD 35.65 |
Jan. 14, 2025 | USD 35.65 | 0.99% |
|
United States |
|
35 |
USD 35.62 |
Jan. 14, 2025 | USD 35.62 | -8.62% |
|
United States |
|
36 |
USD 35.57 |
Jan. 14, 2025 | USD 35.57 | -5.10% |
|
United States |
|
37 |
USD 34.59 |
Jan. 14, 2025 | USD 34.59 | -0.52% |
|
United States |
|
38 |
USD 33.93 |
Jan. 14, 2025 | USD 33.93 | -12.73% |
|
United States |
|
39 |
USD 32.50 |
Jan. 14, 2025 | USD 32.50 | -12.19% |
|
United States |
|
40 |
USD 31.64 |
Jan. 14, 2025 | USD 31.64 | -2.65% |
|
United States |
|
41 |
USD 30.05 |
Jan. 14, 2025 | USD 30.05 | -12.49% |
|
United States |
|
42 |
USD 29.74 |
Jan. 14, 2025 | USD 29.74 | 7.48% |
|
United States |
|
43 |
USD 28.56 |
Jan. 14, 2025 | USD 28.56 | -4.90% |
|
United Kingdom |
|
44 |
USD 27.52 |
Jan. 14, 2025 | USD 27.52 | 8.65% |
|
United States |
|
45 |
USD 27.05 |
Jan. 14, 2025 | USD 27.05 | -4.79% |
|
United States |
|
46 |
USD 25.46 |
Jan. 14, 2025 | USD 25.46 | -2.64% |
|
United States |
|
47 |
USD 25.38 |
Jan. 14, 2025 | USD 25.38 | 0.87% |
|
United States |
|
48 |
USD 24.98 |
Jan. 14, 2025 | USD 24.98 | -2.76% |
|
United States |
|
49 |
USD 24.85 |
Jan. 14, 2025 | USD 24.85 | -2.24% |
|
United States |
|
50 |
USD 23.67 |
Jan. 14, 2025 | USD 23.67 | -3.70% |
|
Netherlands |
The Clinical Trials company with the highest Share Price is Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX) at USD 411.66.
The Clinical Trials company with the lowest Share Price is Can-Fite BioPharma Ltd. (Tel Aviv Stock Exchange: CANF.TA) at USD 0.01.
The top 10 Clinical Trials companies the Global by Share Price are Vertex Pharmaceuticals Incorporated, Medpace Holdings, Inc., Madrigal Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Genmab A/S, ICON Public Limited Company, Charles River Laboratories International, Inc., Krystal Biotech, Inc., Neurocrine Biosciences, Inc. and Intra-Cellular Therapies, Inc..
The bottom 10 Clinical Trials companies by Share Price are Can-Fite BioPharma Ltd., BioLineRx Ltd., Ovoca Bio plc, Purple Biotech Ltd., ImmuPharma plc, GENinCode plc, Verici Dx plc, Kancera AB (publ), Aptahem AB (publ) and Scancell Holdings plc.